Degatide (Degarelix) Injection

Description

Description

This page contains brief details about the drug degarelix, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Degarelix is an anticancer medication that was approved for its medical use on 24th December 2008.

Mechanism of Action of Degarelix

Degarelix Injection is a biological agent that acts as hormonal drug therapy in cancer treatment. It is the only antagonist of Androgen Deprivation Therapy that works instantly to reduce testosterone levels. Degarelix is a gonadotropin-releasing hormone agonist that binds to the gonadotropin receptors of the pituitary gland. It lowers the release of gonadotrophin and testosterone, eventually inhibiting the development of cancer cells. Degarelix is prescribed alone and also with other anti-androgen medications to treat hormonal cancer.

Uses of Degarelix

Degarelix Injection has been developed to treat advanced prostate cancer in adult men.

Degarelix Dosage available

Degarelix is available as a vial for injection in doses 80mg and 120mg. It is intended for administration through the subcutaneous route. The recommended initial dose is 240mg given as two 120 mg injections and 80mg is injected every 28 days as a maintenance dose.